Adverse effects of beta-agonists: are they clinically relevant? (Q35627643)

9 August 2017

1 reference

title

Adverse effects of beta-agonists: are they clinically relevant? (English)

1 reference

9 August 2017

Michael J Abramson

1

1 reference

9 August 2017

Julia Walters

series ordinal

2

1 reference

9 August 2017

E Haydn Walters

series ordinal

3

1 reference

9 August 2017

1 January 2003

1 reference

Treatments in Respiratory Medicine

9 August 2017

1 reference

9 August 2017

2

1 reference

9 August 2017

4

1 reference

9 August 2017

287-297

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03256657

9 August 2017

0 references

cites work

Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Optimal dose of salbutamol respiratory solution: comparison of three doses with plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

End of the New Zealand asthma mortality epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Optical illusions from visual data analysis: example of the New Zealand asthma mortality epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

International trends in sales of inhaled fenoterol, all inhaled beta-agonists, and asthma mortality, 1970-1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Asthma and the beta agonist debate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

The use of beta-agonists and the risk of death and near death from asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Are asthma medications and management related to deaths from asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

A case-control study of deaths from asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Confounding by severity does not explain the association between fenoterol and asthma death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

A comparison of asthma deaths and near-fatal asthma attacks in South Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Epidemiologic studies of beta agonists and asthma deaths.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Asthma medications and disease exacerbations: an epidemiological study as a method for asthma surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Case-control study of salmeterol and near-fatal attacks of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Risk of myocardial ischaemia and beta-adrenoceptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

beta-adrenergic agonist resistance in normal human airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Airway and metabolic responsiveness to intravenous salbutamol in asthma: effect of regular inhaled salbutamol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Regular inhaled beta-agonist treatment in bronchial asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Salmeterol tachyphylaxis in steroid treated asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Functional antagonism: tolerance produced by inhaled beta 2 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Potential masking effects of salmeterol on airway inflammation in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

An explanation of the asthma paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

The anti-inflammatory profile of inhaled corticosteroids combined with salmeterol in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Effect of a long-acting beta2-agonist over three months on airway wall vascular remodeling in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256657

Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC)

21 January 2018

1 reference

28 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1183/09031936.98.12020315

Identifiers

DOI

10.1007/BF03256657

1 reference

release_v25s6pldirgchfmb3jbm7lc27a

9 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v25s6pldirgchfmb3jbm7lc27a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference